Squamous cell carcinoma of head and neck

• MK-3475 (SCH 9000475) as neoadjuvant and adjuvant therapy in Stage III-IVA resectable LA HNSCC (Locoregionally Advanced Head and Neck Squamo … Recruitment ended
  2022-500254-41-00 5 2018-12-13 "Stage III-IVA Resectable Locoregionally Advanced Head and Ne"
• Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Recruitment ended
  2024-513964-24-00 5 2017-09-14 "Squamous cell carcinoma, previously untreated Stage III, sta"
• Comparing two treatment regimen for sinuses tumors and salivary glands: radiotherapy versus chemoradiotherapy Recruitment ended
  2024-513972-16-00 5 2017-01-30 "- Resected tumors of sinuses or salivary glands - Non-operab"
• A Study of PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors Ended
  2024-514745-10-00 1 2025-06-23 "Melanoma (or) malignant melanoma Non-small cell lung cancer "
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DG … Ended
  2023-503996-38-00 1 2025-05-21 "Advanced or metastatic solid tumors"
• FIH study of ALE.C04 anti-CLDN1 mAb monotherapy or in combination with pembrolizumab in patients with R/M HNSCC Ended
  2023-505145-93-00 7 2024-03-21 "Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Ca"
• A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 … Ended
  2023-506092-10-00 4 2024-03-11 "Stage III-IVA Resectable Locoregionall Advanced Head and Nec"
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3 … Ended
  2023-505322-34-00 1 2024-01-08 "Advanced or metastatic solid tumors"
• A study to evaluate the safety, tolerability and distribution of TB0010 in head and neck squamous cell carcinoma Ended
  2024-517779-19-00 1 2024-01-05 "EGFR-Positive Head and Neck Squamous Cell Carcinoma"
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma Ended
  2023-503418-63-00 4 2023-11-23 "Head and Neck Squamous Cell Carcinoma"
• Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer Ended
  2022-502339-20-00 4 2023-11-15
• Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors Ended
  2022-502787-20-00 4 2023-09-28 "Melanoma and squamous cell carcinoma of the head and neck"
• A study to investigate the safety and tolerability of intravenous QEQ278 in patients with advanced solid tumors Ended
  2022-500540-38-00 1 2023-06-27 "Non-small cell lung cancer Oesophageal squamous cell carcino"
• Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors Ended
  2022-500694-14-00 7 2023-06-02 "Head and Neck Squamous Cell Cancer"
• INCA 32459-101: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies Ended
  2022-501505-13-00 1 2023-03-31 "Metastatic melanoma"
• A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies Ended
  2023-504400-29-00 1 2022-09-15 "Advanced malignancies."
• A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended
  2023-505455-44-00 9 2022-06-29 "Solid tumours"
• Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies Ended
  2022-500868-36-00 1 2021-08-11 "Squamous Cell Carcinoma of Head and Neck"
• A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) Ended
  2023-508340-22-00 4 2021-08-11 "metastatic or unresectable, recurrent HNSCC"
• A Phase 2 study of ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma … Ended
  2023-508342-17-00 4 2021-08-11 "metastatic or unresectable, recurrent HNSCC"
• Trial evaluating the tolerance and safety of durvalumab - radiotherapy combination for treatment of cancers of the head and neck Ended
  2024-513977-31-00 4 2019-07-17 "Untreated squamous cell carcinoma of the head and neck"
• A clinical study to investigate if the investigational products, called LN-144 and LN-145 (also known as Tumour Infiltrating Lymphocytes), a … Ended
  2024-510779-39-00 4 2018-12-19 "Neoplasm"
• ABIMMUNE: A Phase I/II study evaluating the safety and clinical activity of anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) a … Ended
  2024-514920-18-00 9 2017-06-20 "Metastatic squamous cell carcinoma of head and neck, lung, e"
• Phase II study evaluating peptide-based immunotherapies as monotherapy for 3 weeks prior to standard treatment for head and neck cancer. Ended
  2024-513447-82-00 4 "squamous cell carcinoma of the head and neck"

Showing 25–48 of 48 trials